Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Syngene Makes Strong Debut On Indian Bourses

This article was originally published in Scrip

Executive Summary

Syngene International has made a strong debut on Indian bourses listing at INR295 ($4.6) and closing higher, even as the overall market declined in the country. Syngene is the research services arm of Biocon.

You may also be interested in...



Biocon’s Malaysia Insulin Plant Wins EU Clearance, Company Is Open To PE Investment

Biocon has received European regulatory clearance for its new Malaysian insulin plant and also said it is open to private-equity investment proposals for its fast-growing biologics division ahead of a planned IPO.

M&A Trends: The Growing Indian Appetite

A recent round table on pharma industry trends has highlighted the hunger of cash-rich Indian firms for acquiring companies with niche portfolios in regulated markets including the US. Innovator companies shedding their generic units also present significant opportunities for Indian firms. Both trends are expected to build amid apparent Indian interest in the Teva-Allergan divestiture in Europe.

Asia Deal Watch: China Grand, ETheRNA Create mRNA Vaccine JV

Plus deals involving LegoChem/Pyxix, Biohaven/Sosei Heptares, Kyowa Kirin/Helsinn, Dr. Reddy’s/Glenmark, Eisai/Wren, KoBioLabs/Kolmar Korea, Y-Biologics/Pierre Fabre, Generex/Chinese consortium.

Topics

Related Companies

UsernamePublicRestriction

Register

OM006664

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel